PAH is a rare and serious condition where high pressure in the lung's arteries strains the right heart. Targeted combination therapies have dramatically extended survival — but the disease still requires expert management.
PAH affects 15–50 people per million. Women are diagnosed 3× more often than men. Early treatment initiation is the strongest predictor of long-term outcomes.
🕐 Last updated: March 23, 2026📡 Sources: NIH · CDC · FDA · ClinicalTrials.gov12 articles
🔔
Get PAH Alerts
Free weekly updates from NIH, CDC & FDA when new research drops. No spam. Unsubscribe anytime.
Clinical TrialFebruary 20, 2026
PAH Clinical Trials 2026: Emerging Therapies and What's in the Pipeline
The PAH pipeline in 2026 is advancing on multiple fronts, building on the transformative sotatercept approval to explore disease modification and potentially curative approaches.
Key ongoing and recently reported trials: The ZENITH trial is studying sotatercept in WHO FC II patients — earlier in the disease course where modification of vascular remodeling may have maximum impact. The ADVANCE OUTCOMES trial is evaluating sotatercept's effect on morbidity and mortality as a primary endpoint (vs. STELLAR's 6MWT endpoint). Combination of sotatercept with initial triple oral therapy is being explored in investigator-initiated trials.
Gene therapy approaches targeting BMPR2 mutations (the most common genetic cause of heritable PAH) are in early clinical development. Ralinepag, a second-generation oral prostacyclin receptor agonist, showed Phase 2 efficacy data. Several trials are examining the role of GDF/activin pathway inhibition beyond sotatercept. Anti-inflammatory and metabolic approaches (metformin in PAH via METPAH; dichloroacetate targeting metabolic reprogramming of pulmonary vascular cells) are in Phase 1/2. The Pulmonary Hypertension Association (PHAssociation.org) maintains a searchable clinical trial database and offers patient matching support for any PAH patient interested in participating.
Transplant Evaluation for PAH: When to Refer and What to Expect
Lung transplantation (bilateral lung transplant or combined heart-lung transplant) remains an option for PAH patients who deteriorate despite maximally optimized medical therapy. With the advances in targeted therapy over the past decade, fewer PAH patients progress to transplant — but it remains important to refer early enough to allow time for evaluation and listing.
Indicators for transplant referral: rapidly deteriorating WHO FC despite triple combination therapy, significant hemodynamic deterioration (TAPSE <1.5 cm, CI <2 L/min/m², RA pressure >15 mmHg), BNP/NTproBNP continuing to rise, multiple hospitalizations, syncope at rest or with minimal exertion, and pericardial effusion. The Pulmonary Hypertension Association recommends referral when WHO FC III despite 3 months of optimized therapy, or immediately for WHO FC IV.
Once listed, median wait time for lung transplantation in the US is 2–4 years, though the Lung Allocation Score (LAS) system prioritizes sicker patients. Five-year survival post-transplant for PAH is approximately 50%, which is lower than transplant for other diagnoses but substantially better than the prognosis of medically refractory advanced PAH. Heart-lung transplant is reserved for patients with significant biventricular failure or uncorrectable congenital cardiac anatomy. Experienced PAH centers — PHA-accredited Pulmonary Hypertension Care Centers — should guide transplant timing decisions.
PDE5 Inhibitors and sGC Stimulators in PAH: Sildenafil, Tadalafil, and Riociguat
The nitric oxide-cGMP pathway is one of three major therapeutic targets in PAH. Nitric oxide (NO) normally relaxes pulmonary arterial smooth muscle by increasing intracellular cyclic GMP (cGMP). Two drug classes enhance this pathway: phosphodiesterase-5 inhibitors (PDE5i), which prevent cGMP breakdown, and soluble guanylate cyclase (sGC) stimulators, which directly stimulate cGMP production.
Sildenafil (Revatio): The first PDE5i approved for PAH (2005). 20 mg three times daily. The SUPER-1 trial showed significant 6MWD improvement. Generic versions are now widely available, making it the most affordable targeted PAH therapy. Main side effects: headache, flushing, hypotension, visual disturbances. Cannot be combined with nitrates or riociguat (risk of severe hypotension).
Tadalafil (Adcirca): Once-daily dosing advantage over sildenafil (40 mg once daily). PHIRST trial showed superior 6MWD improvement vs. placebo. Often preferred for its convenience and successful use in the AMBITION combination trial. Generic available since 2019.
Riociguat (Adempas): Stimulates sGC by a mechanism independent of NO availability — effective even in the setting of oxidative stress that degrades NO. Approved for both PAH and inoperable/persistent chronic thromboembolic pulmonary hypertension (CTEPH, Group 4) — the only drug approved for both. The PATENT-1 trial showed significant 6MWD improvement. Riociguat is teratogenic — requires REMS enrollment for women of childbearing potential. It cannot be combined with PDE5 inhibitors.
Sotatercept for PAH: A New Mechanism and What the STELLAR Trial Shows
Sotatercept (Winrevair, Merck) received FDA approval in March 2024 — the first truly novel PAH mechanism in over a decade. Unlike existing therapies that target vasoconstriction, sotatercept is an activin signaling inhibitor (fusion protein trapping activin A and other TGF-β ligands) that addresses the aberrant vascular cell proliferation and remodeling underlying PAH. It doesn't just manage symptoms — it targets disease modification at a structural level.
The Phase 3 STELLAR trial enrolled 323 WHO FC II-III PAH patients on background PAH therapy and randomized them to sotatercept 0.7 mg/kg subcutaneous every 3 weeks vs. placebo. Results: sotatercept improved 6MWT by 40.8 meters vs. placebo, significantly reduced PVR (the first drug to show meaningful PVR reduction in a Phase 3 trial on background therapy), improved WHO functional class in 36% of patients, and reduced time to death or worsening. BNP and right ventricular strain markers also improved significantly.
Sotatercept is administered subcutaneously every 3 weeks by injection (self-administration is possible after training). The main side effects include telangiectasias (spider veins), increased hemoglobin (polycythemia, which may require dose adjustment), and dizziness. It's indicated for adults with PAH WHO Group 1 in combination with other PAH therapies. This addition to the treatment algorithm — a fourth combination partner — represents the most significant advance in PAH pharmacotherapy in years.
PAH and Pregnancy: Understanding the Serious Risks
Pregnancy in PAH carries very high maternal mortality — historically estimated at 30–56%, though more recent series from expert centers suggest this may be improving to 10–25% with intensive multidisciplinary management. PAH is considered a contraindication to pregnancy by all major cardiology and obstetrics societies. This is one of the most important counseling points for any woman of reproductive age with PAH.
Why pregnancy is dangerous in PAH: The physiological changes of pregnancy — increased cardiac output, increased blood volume, systemic vasodilation — all stress the right ventricle, which is already under severe strain. Labor and delivery create acute hemodynamic shifts. The immediate postpartum period is the highest-risk window, when return of uterine blood volume combined with falling peripheral resistance can precipitate acute right ventricular failure.
For women who become pregnant despite this guidance: immediate referral to a PAH center with maternal-fetal medicine co-management is essential. Continuing targeted PAH therapy is critical — abrupt drug discontinuation in pregnancy can be fatal. Delivery planning (timing, mode, anesthesia) must be individualized and performed at a center experienced in managing PAH in pregnancy. Women with PAH who wish to avoid pregnancy should use effective contraception; estrogen-containing contraceptives are relatively contraindicated due to thrombosis risk, making progestin-only methods or non-hormonal options preferable.
Right Heart Catheterization for PAH: What to Expect
Right heart catheterization (RHC) is the gold standard for diagnosing PAH — not echocardiography. While echo can screen for pulmonary hypertension, only RHC provides the pressure measurements and pulmonary vascular resistance values required for a definitive PAH diagnosis and for distinguishing Group 1 PAH from other pulmonary hypertension types.
During RHC: you'll be lightly sedated but awake. A thin catheter is inserted into a large vein (typically the right internal jugular or femoral vein) and advanced through the right heart chambers into the pulmonary artery. The procedure measures mean pulmonary artery pressure (mPAP), pulmonary capillary wedge pressure (PCWP), cardiac output, and pulmonary vascular resistance (PVR). A vasoreactivity test using inhaled nitric oxide or IV adenosine may be performed — important because the rare subset of patients (5–10%) who test "positive" (mPAP drops ≥10 mmHg to below 40 mmHg) may respond to high-dose calcium channel blockers and have significantly better prognosis.
The procedure typically takes 30–60 minutes. Serious complications are uncommon (<1%) at experienced centers and include arrhythmia, vessel injury, and air embolism. RHC is repeated periodically (often at 12 months) to assess treatment response — improvement in PVR is one of the strongest predictors of long-term outcomes.
The 6-Minute Walk Test in PAH: What the Number Means
The 6-minute walk test (6MWT) is the most widely used functional outcome measure in PAH. It measures how far a patient can walk on a flat, hard surface in 6 minutes — a simple, inexpensive test that captures exercise tolerance and correlates with PAH severity, prognosis, and treatment response.
Normal 6MWT distance is 400–700 meters. In PAH, the baseline distance reflects disease severity: distances below 300 meters are associated with significantly worse prognosis, while distances above 380–400 meters generally indicate WHO FC II disease. Clinical trials routinely use 6MWT distance as a primary endpoint, and many guidelines use specific thresholds (e.g., <330 m, <440 m) as part of risk stratification.
Important caveats: 6MWT is influenced by age, sex, height, weight, and patient effort, making absolute numbers less informative than changes over time within the same patient. A meaningful improvement in trials is generally ≥33 meters, though some experts argue for higher thresholds. Your 6MWT at baseline and follow-up visits provides a concrete number your specialist tracks alongside WHO functional class, biomarkers (BNP/NTproBNP), and right heart catheterization data to assess how well PAH is controlled and whether treatment escalation is needed.
WHO Functional Class in PAH: What Your Classification Means
The World Health Organization (WHO) Functional Classification is the standard system for assessing how much PAH limits a patient's physical activity. It's adapted from the New York Heart Association (NYHA) cardiac classification and guides treatment decisions in PAH.
WHO FC I: No limitations. Ordinary physical activity does not cause symptoms. FC II: Slight limitation. Comfortable at rest, but ordinary activity causes dyspnea or fatigue. FC III: Marked limitation. Comfortable at rest, but less-than-ordinary activity causes symptoms. FC IV: Unable to carry out any activity without symptoms. Dyspnea may be present at rest.
In practice, most PAH patients are diagnosed at FC II or III. FC IV indicates urgent need for escalation, often including IV epoprostenol. Your functional class drives treatment decisions: dual oral combination is recommended for FC II-III; prostacyclin therapy is urgently added at FC IV. FC also predicts prognosis — patients maintaining FC I-II on treatment have far better survival than those at FC III-IV. Regular FC assessment (every 3–6 months) with 6-minute walk testing is standard in PAH follow-up. Improvement of even one functional class on treatment is a meaningful clinical outcome.
Combination Therapy in PAH: Why Two (or Three) Drugs Beat One
PAH treatment has moved decisively toward upfront combination therapy — simultaneously targeting multiple pathways — rather than starting with one drug and escalating. This shift was driven by clear trial evidence that combination therapy produces better outcomes than sequential monotherapy.
The turning point was AMBITION (2015), which randomized treatment-naïve WHO FC II-III patients to ambrisentan plus tadalafil vs. either monotherapy. The combination reduced clinical failure events by 50% and was superior on essentially all secondary endpoints. The concept: the three major PAH pathways (nitric oxide, endothelin, prostacyclin) operate independently, so blocking all three simultaneously is more effective than blocking one at a time.
Current guidelines recommend upfront dual oral combination therapy (ERA + PDE5i or sGC stimulator) for most treatment-naïve PAH patients. For higher-risk or rapidly deteriorating patients, triple combination including a prostacyclin is the target. The TRITON trial studied initial triple combination (macitentan + tadalafil + selexipag) and found a trend toward improved pulmonary vascular resistance vs. dual, though outcomes benefit requires longer follow-up. Risk stratification (REVEAL, REVEAL Lite 2) guides treatment intensity and frequency of escalation.
Endothelin Receptor Antagonists for PAH: Bosentan, Ambrisentan, and Macitentan
Endothelin-1 (ET-1) is a potent vasoconstrictor and smooth muscle mitogen overexpressed in PAH. Blocking its receptors (ETA and ETB) reduces pulmonary vascular resistance, improves exercise capacity, and slows disease progression. Three endothelin receptor antagonists (ERAs) are FDA-approved for PAH.
Bosentan (Tracleer): The first ERA approved (2001), a dual ETA/ETB blocker. It has the longest safety record but is associated with dose-dependent aminotransferase elevation (hepatotoxicity) requiring monthly liver function test monitoring. Available generically, making it more affordable than the newer agents. The BREATHE-1 trial established its efficacy in improving 6-minute walk distance (6MWD) and WHO functional class.
Ambrisentan (Letairis): Selective ETA blocker. The ARIES trials showed improvements in 6MWD, WHO FC, and time to clinical worsening. Lower risk of hepatotoxicity than bosentan (no routine LFT monitoring required). Once-daily dosing. The combination of ambrisentan plus tadalafil (AMBITION trial) demonstrated superiority over monotherapy in treatment-naïve WHO FC II-III patients.
Macitentan (Opsumit): Dual ETA/ETB blocker with enhanced tissue penetration. The SERAPHIN trial used a morbidity/mortality endpoint (unusual for PAH trials at the time) and showed a 45% risk reduction in clinical worsening. Monthly LFT monitoring not required. Now the preferred ERA in many treatment algorithms given its morbidity/mortality data.
Prostacyclin Pathway Therapies Compared: Epoprostenol, Treprostinil, Iloprost, and Selexipag
The prostacyclin pathway is the most potent vasodilatory mechanism targeted in PAH. Prostacyclins relax pulmonary arterial smooth muscle, inhibit platelet aggregation, and have antiproliferative effects on vascular remodeling. Four agents targeting this pathway are approved for PAH.
Epoprostenol (Flolan, Veletri): The original prostacyclin. IV only, continuous infusion via central line. It has a half-life of 3–5 minutes, requiring uninterrupted infusion — pump malfunction or line disconnection is life-threatening. Despite this complexity, it remains the most effective therapy for WHO FC IV patients and those failing oral/inhaled therapy. Veletri is room-temperature stable; Flolan requires refrigeration.
Treprostinil (Remodulin, Orenitram, Tyvaso): Available in IV, subcutaneous, inhaled (Tyvaso), and oral (Orenitram) forms. Subcutaneous treprostinil avoids central line risk but causes significant injection-site pain. Inhaled treprostinil (Tyvaso) was shown in TRIUMPH-1 to improve walk distance on top of background ERA or PDE5i therapy. Oral treprostinil (FREEDOM-C trials) has more modest efficacy.
Iloprost (Ventavis): Inhaled only, 6–9 times daily. The dosing frequency limits long-term adherence.
Selexipag (Uptravi): Oral IP receptor agonist (not a prostacyclin but same receptor). GRIPHON trial: 40% risk reduction in composite morbidity/mortality endpoint. Conveniently oral, twice daily. First-line-eligible as part of initial triple combination therapy.
What Is Pulmonary Arterial Hypertension (PAH)? A Plain-English Overview
Pulmonary arterial hypertension (PAH) is a rare and serious condition where abnormally high blood pressure in the arteries of the lungs forces the right side of the heart to work harder than it should. Over time, this leads to right ventricular failure — the primary cause of death in PAH.
PAH is classified as Group 1 pulmonary hypertension under the WHO classification system. This distinguishes it from more common forms of pulmonary hypertension caused by left heart disease (Group 2), lung disease (Group 3), or chronic blood clots (Group 4). The distinction matters because only Group 1 PAH responds to the targeted therapies that have transformed the disease.
Diagnosis requires right heart catheterization confirming mean pulmonary arterial pressure (mPAP) ≥20 mmHg with pulmonary vascular resistance ≥2 Wood Units and pulmonary capillary wedge pressure ≤15 mmHg. PAH affects an estimated 15–50 people per million worldwide, with women diagnosed 2–4 times more frequently than men. Associated conditions include connective tissue disease (especially scleroderma), HIV infection, portal hypertension, congenital heart disease, and drug/toxin exposure. About 30–40% of PAH is idiopathic.
My Sugar Pill may earn a commission when you book — at no extra cost to you. One way we keep My Sugar Pill free.
About this content
Sourced from U.S. government health agencies (NIH, CDC, FDA) and ClinicalTrials.gov. Summaries are written in plain English. Always consult your doctor before making healthcare decisions. My Sugar Pill does not provide medical advice.
About My Sugar Pill · No sponsored content · No data selling · Free, always.